Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health reported another year of rapid growth in 2025. Full-year revenue reached $2.35 billion, up 59%, with subscribers ending at 2.5 million, a 13% increase. Net income was broadly stable at $128.4 million, while Adjusted EBITDA jumped to $318.0 million from $176.9 million, showing stronger underlying profitability.
In the fourth quarter, revenue was $617.8 million, up 28% year over year. Net income declined to $20.6 million, but Adjusted EBITDA improved to $66.3 million. Gross margin compressed to 74% for 2025 from 79%, reflecting mix shifts toward new offerings and international markets.
Operating cash flow rose to $300.0 million in 2025, but Free Cash Flow fell to $57.4 million as the company stepped up capital spending on pharmacies, technology, and infrastructure. For 2026, it guides revenue to $2.7–$2.9 billion and Adjusted EBITDA to $300–$375 million, indicating continued growth while funding expansion.
Hims & Hers Health, Inc. agreed to acquire Australia-based digital health company Eucalyptus for an enterprise value of up to $1,150,000,000, subject to customary adjustments. About $240,000,000 is payable in cash at closing, with additional deferred and earnout payments extending up to early 2029.
The structure relies heavily on deferred consideration of approximately $710,000,000 and potential earnouts of up to approximately $200,000,000, some of which Hims & Hers can settle in Class A common stock at its election. The deal is expected to close around the middle of fiscal year 2026, expanding Hims & Hers’ presence in Australia, Japan, the UK, Germany and Canada.
Hims & Hers Health, Inc. reported that institutional investor Capital World Investors beneficially owns 14,322,912 shares of its common stock, representing 6.5% of the class, based on 219,270,891 shares believed to be outstanding as of the ownership date.
Capital World Investors reports sole voting power over 14,316,043 shares and sole dispositive power over 14,322,912 shares, with no shared voting or dispositive power. The shares are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Hims & Hers Health, Inc.’s Chief Financial Officer, Oluyemi Okupe, reported an option exercise and share sale in Class A Common Stock on February 3, 2026.
He exercised 5,262 stock options at an exercise price of $5.01 per share, then sold 5,262 shares of Class A Common Stock at an average price of $26.4363 per share under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he directly owned 91,617 shares of Class A Common Stock and 144,051 stock options, and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported stock option exercises and a share sale. On January 20, 2026, the CFO exercised stock options for 7,317 Class A Common shares at an exercise price of $5.01 per share and for 1,750 shares at $11.53 per share. That same day, 9,067 Class A Common shares were sold at a weighted average price of $30.3423, with actual sale prices ranging from $30.21 to $30.44.
After these transactions, the CFO directly owned 91,617 Class A Common shares and held stock options covering 149,313 and 42,996 shares in two separate option awards. An additional 7,853 shares were held indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing states that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025, which is a pre-arranged program for trading company stock.
Form 144 indicates a planned sale of 27,204 shares of HIMS common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of $828,905.88. These shares relate to stock options granted as compensation and acquired via cashless exercise and same-day sale transactions dated 02/24/2022 and 03/01/2023.
The notice lists 219,270,891 common shares outstanding and details prior sales by Oluyemi Okupe over the past three months, including multiple blocks of common stock sold on 11/17/2025, 12/22/2025, and 01/05/2026 with specified share amounts and gross proceeds.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe reported option exercises and a stock sale involving Class A common stock. On January 5, 2026, Okupe exercised stock options for 2,178 shares at $5.01 and 3,808 shares at $11.53 per share, receiving the same number of Class A shares. On the same day, Okupe sold 9,070 shares of Class A common stock at an average price of $33.7875.
The filing states that these option exercises and sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025. After the reported transactions, Okupe directly held 91,617 Class A shares and indirectly held 7,853 additional shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock. On 12/22/2025, the reporting person sold 23,090 shares at an average price of $35.7172, with trades executed in a price range of $35.36–$35.88. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025, which is designed to systematically execute trades over time.
After this transaction, the reporting person beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.
HIMS insider Oluyemi Okupe has filed a Rule 144 notice to sell up to 32,160 shares of common stock through Goldman Sachs & Co. LLC. The planned sale has an aggregate market value of $1,127,208, with the shares listed on the NYSE and 219,270,891 shares of this class outstanding. The shares come from equity compensation, including restricted stock units and stock options acquired between February 2022 and December 2025, with some tied to cashless, same-day option exercises.
Over the prior three months, the same seller completed several sales of HIMS common stock, ranging from 11,592 to 85,000 shares per transaction, for gross proceeds between roughly $669,232 and $5,116,923.50. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported selling 13,750 shares of Class A common stock on 12/17/2025 at $36.71 per share. The transaction was reported with transaction code "S" and was effected under a Rule 10b5-1 trading plan adopted on March 4, 2025.
After this sale, Chi beneficially owns 305,161 shares of Hims & Hers Health, Inc. common stock in direct ownership.